What is Transcarent?
One Place for Health and Care for employers and health plans
- Category
- Health benefits navigation
- Headquarters
- San Francisco, California
- Founded
- 2020
- Employees
- About 501-1,000 employees
- Total funding
- Approximately $450M
- Valuation or Status
- $2.2B valuation in May 2024 Series D
What is Transcarent?
Transcarent is one place for health and care for employers and health plans.
Transcarent is one place for health and care for employers and health plans, operating in health benefits navigation. Transcarent is a health-benefits platform for self-insured employers, health plans, and members, combining navigation, virtual care, pharmacy, surgery, behavioral health, cancer, and AI-guided care experiences. Its careers page says it helps millions of employers and health plans make care easier to access.
As of June 2026, the company is best understood as a private growth company with About 501-1,000 employees, Approximately $450M, and $2.2B valuation in May 2024 Series D. For sellers, the useful signal is where the company is concentrating spend: product velocity, compliance, data, infrastructure, customer success, and go-to-market systems that support its next stage.
What does Transcarent offer?
Transcarent offers Just Ask Transcarent, Everyday Care, Pharmacy Care, Surgery Care, and related products for its market.
- Just Ask Transcarent· AI navigation
- Everyday Care· Virtual care
- Pharmacy Care· Pharmacy
- Surgery Care· Centers of excellence
- Cancer Care· Complex care
- Care@Home· Care delivery
How does Transcarent make money?
Transcarent makes money by contracting with self-insured employers and health plans to simplify care access and reduce cost.
Transcarent makes money by contracting with self-insured employers and health plans to simplify care access and reduce cost. Growth is driven by covered lives, employer wins, care-program adoption, AI navigation, and outcomes in high-cost categories such as pharmacy, surgery, cancer, and behavioral health. Transcarent sells enterprise contracts to employers and health plans; pricing is not public and may include platform fees, PMPM economics, risk/value-based arrangements, care-program fees, and performance guarantees.
Because Transcarent is private, public revenue and margin disclosure is limited unless noted in recent reporting. The practical budget signal is the company's current operating motion: hiring, new product launches, customer expansion, and financing that funds engineering, security, data, compliance, and sales capacity.
Who leads Transcarent?
Transcarent's leadership centers on Glen Tullman and Snezana Mahon, PharmD.
- Glen TullmanChief Executive OfficerCEO since 2021Former Livongo founder and CEO.
- Snezana Mahon, PharmDPresidentCurrent presidentHealthcare executive leading platform and care strategy.
- Stephanie PengChief Financial OfficerCurrent CFOFinance leader on Transcarent's executive team.
- Kristen BruzekExecutive leaderCurrent executive teamListed on Transcarent's leadership team.
How do you contact Transcarent's leadership?
Transcarent publishes contact forms and sales paths, not personal executive emails.
Personal executive email format not verified; use transcarent.com contact forms- Glen TullmanChief Executive OfficerPersonal executive email format not verified; use transcarent.com contact forms
- Snezana Mahon, PharmDPresidentPersonal executive email format not verified; use transcarent.com contact forms
- Stephanie PengChief Financial OfficerPersonal executive email format not verified; use transcarent.com contact forms
- Kristen BruzekExecutive leaderPersonal executive email format not verified; use transcarent.com contact forms
How much funding has Transcarent raised?
Transcarent has Approximately $450M; latest valuation/status: $2.2B valuation in May 2024 Series D.
Transcarent has Approximately $450M; latest valuation/status: $2.2B valuation in May 2024 Series D. October 2020: Series A — $40M. Early financing for Transcarent's consumer-directed health platform. June 2021: Series B — $58M. Round brought total funding to $98M. 2022: Series C — amount not fully repeated in latest release. Series C brought the company above unicorn status with health-system and investor participation. May 2024: Series D — $126M at $2.2B valuation. General Catalyst and 7wireVentures led; total funding reached approximately $450M.
Where a round amount or valuation has not been publicly disclosed, this profile says so rather than filling the gap. The seller signal is whether the latest financing created budget for hiring, infrastructure, compliance, enterprise sales, or geographic expansion.
How did Transcarent get here?
Transcarent's milestones show its path from founding to its current health benefits navigation position.
- 2020Transcarent launchedThe company formed to simplify employer-sponsored healthcare.
- 2021Glen Tullman joined as CEOThe Livongo founder became CEO.
- 2021Series B closedTranscarent raised $58M and scaled its risk-based offering.
- 2024Series D at $2.2BThe company raised $126M and reported about $450M total funding.
- 2025Accolade merger/integration focusMarket commentary discussed Transcarent and Accolade integration as part of care-navigation consolidation.
- 2026One Place positioningThe brand centered on a single AI-enabled access point for health and care.
Who are Transcarent's competitors?
Transcarent competes with category specialists and broader platforms serving the same buyer or user workflow.
- Included HealthEmployer health navigation, virtual care, and care concierge platform.
- AccoladeBenefits navigation and advocacy platform integrated into Transcarent's market narrative.
- Quantum HealthHealthcare navigation and care coordination for employers.
- apree healthAdvanced primary care and navigation company.
- Carrum HealthCenters-of-excellence marketplace for surgeries and specialty care.
- Sword HealthAI care company expanding from MSK into broader health categories.
Transcarent — frequently asked questions
